full in Biological Technology
Navigation Links
full in Biological Technology
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... -36% Non GAAP diluted earnings per ADS (using full year expected tax rate: 24%) ... SUMMARY Second Quarter 2009 (see page 6 for full Financial Results) - Product sales excluding ... in Q2 2009 compared to Q2 2008. Using a full year expected effective tax rate of 24%, ...Five Questions About Protopic (tacrolimus) Ointment
... www.protopic.com for more information including full prescribing information. References ... page 3 Protopic(R) (tacrolimus) Ointment full Prescribing Information, Deerfield, Ill., ... Inc. 2006 Protopic(R) (tacrolimus) Ointment full Prescribing Information, Deerfield, Ill., ...Caliper Life Sciences Reports Second Quarter 2009 Results
... 2009 Guidance The Company projects full year revenue of $126 to $129 million, which ... over the second half of 2009 and for the full year 2010. Caliper reported that its ... over the second half of 2009 and for the full year 2010, Caliper's expected revenue outlook for ...Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
... are very pleased to once again be increasing our full year 2009 adjusted diluted EPS guidance. At the ... we're now projecting year-over-year growth in full year adjusted diluted EPS of approximately 45%." ... driven mainly by new product launches, and a full six months of revenue contribution from the ...... and a frequent speaker for Candela Laser on their full line of lasers including the top tiered GentleMax ... is the medical director of Total Dermatology, a full service laser, cosmetic and medical dermatology ... for training availability. # # # Read the full story at ...
Spectrum Announces Fetal Bovine Serum Product Line
... stem cell research. Each FBS order includes a full biochemical and chemical profile, as well as ... Canada, and Australia. Each FBS order includes a full biochemical and chemical profile, as well as ... . ### Read the full story at ...Stem cells' 'suspended' state preserved by key step, scientists report
... this state, or even if it is necessary for the full stem cell potential," said Alexandre Gaspar-Maia, ... did so, embryonic stem cells could not make the full range of specialized cells. In a laboratory ... the open condition that may assure the cell's full potential, and the more constrained state that ...Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply
... Hib-containing vaccines to enable the return to a full series of vaccinations for U.S. children. Based ... dose and return to protecting children with the full Hib vaccine series," said Wayne Pisano, president ... or are too young to have received their full primary series. While this is a hypothesis, it's ...... C.F.M. Group, which was announced on Monday. full details of this transaction can be found at ... C.F.M. Group, which was announced on Monday. full details of this transaction can be found at ... +44 (0) 1865 784 177 ### Read the full story at ...
... code bases. In this Software Technology Report, full Spectrum Software offers a guide to updating ... Southborough, MA (Vocus) June 2, 2009 -- full Spectrum Software, a rapidly growing medical ... before developing any medical device software. full Spectrum Software is a medical device software ...
... share guidance for the second quarter 2009 and full year 2009. The Company will issue revised basic ... income guidance for the second quarter 2009 and full year 2009. The sole book-running manager for ... also markets numerous products internationally. full prescribing information on U.S. products is ...
CryoLife Reports Record First Quarter Revenues of $26.7 Million
... The Company is reiterating its guidance for the full year of 2009. The Company's GAAP revenues are ... The Company expects total revenues for the full year of 2009 to be between $113.0 million and ... between $50.0 million and $52.0 million for the full year of 2009. Other medical device revenues, ...Caliper Life Sciences Reports First Quarter 2009 Results
... the remainder of this year and deliver positive full year EBITDA in 2010," added Hrusovsky. ... 4% which is consistent with the Company's full year organic growth estimate of 4-7%. As ... Caliper's expectation to deliver positive full year EBITDA in 2010, Caliper's expected revenue ...Beckman Coulter Announces First Quarter 2009 Results
... Reaffirms full Year Outlook ORANGE COUNTY, Calif., April 28 ... giving us confidence that we will achieve our full year earnings goals. Within the quarter, an ... sequencing business. full Year Outlook "We are affirming our outlook, ...TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower
... to Baptist Hospital East's facility, as well as full outpatient surgery. All of the patient rooms are ... total solution package included the equipment and full installation of 153 Philips commercial and ... Services is uniquely positioned to offer a full suite of hospital technology solutions that ...The Importance of Mixing: How to Compare Lab Scale Mixing with Full Scale Process Vessel Performance
... of Mixing: How to Compare Lab Scale Mixing with full Scale Process Vessel Performance . Process ... reactor compares to the mixing performance of a full scale process vessel which is targeted to receive ... and Chemical Engineering. ### Read the full story at ...China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results
... million, or $0.45 per diluted share full Year 2008 Highlights -- Total revenues ... in the fourth quarter of 2007. full Year 2008 Results For the full year 2008, total revenues were $91.8 million, up ...Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
... month periods ended December 31, 2008. full Year 2008 Financial Highlights -- Record full year 2008 sales increasing 39% year-over-year to ... up from 5.12 million in 2007 -- Record full year net income growing of 5% to $8.01 million ...Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
... month periods ended December 31, 2008. full Year 2008 Financial Highlights -- Record full year 2008 sales increasing 39% year-over-year to ... up from 5.12 million in 2007 -- Record full year net income growing of 5% to $8.01 million ...US Oncology Provides Full Service Management of Clinical Trials
... US Oncology Clinical Development (USOCD), a full service contract research organization (CRO). ... company's extensive resources in order to provide full service CRO capabilities with expertise in the ... US Oncology Clinical Development is a full service CRO providing high quality, cost ...NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
... its financial results for the fourth quarter and full year ended December 31, 2008. The company also ... million in cash and cash equivalents. full Year 2008 Financial Results For the full year 2008, license and collaboration revenue ...IDM Pharma Reports 2008 Financial Results
... financial results for the fourth quarter and full year ended December 31, 2008. Financial ... December 31, 2007. The higher expenses for the full year 2007 included $0.5 million in fees to an ... IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of ...BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
... its financial results for the fourth quarter and full year ended December 31, 2008. "We are very ... per share, for the same period in 2007. For the full year ended December 31, 2008, the Company ... $0.4 million for the same period in 2007. For the full year ended December 31, 2008, revenue was $8.4 ...BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
... period. -- EBITDA was $10.6 million for the full year 2008. Non-GAAP operating income, net ... million in the fourth quarter of 2007. full Year 2008 Financial Results Revenue in the ... announced today that it expects EBITDA for the full year 2009 to reach $16 million to $18 million. ...New Brain Fitness Survey Reinforces Importance of Brain Awareness Week
... public libraries would help." Note: The full results and analysis of the complete survey will ... of over 20 companies, and the results of the full market survey introduced above. ... Alvaro Fernandez, 415-318-3467 ### Read the full story at ...Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results
... CALP ), today reported its fourth quarter and full year financial results for 2008. Fourth quarter ... revenues, our continuing businesses grew 7% in full year 2008 on a pro forma basis. We have strong ... product lines," added Hrusovsky On a full year basis, 2008 revenues were $134.1 million, a ...GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
... for the comparable period in 2007. For the full year of 2008, the Company reported a net loss of ... information is presented below. GeoVax's full set of audited financial statements are included ... responses) at both low (1/10th) dose and full doses. Other highlights of the presentation ...Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
... 17.1% year-over-year growth; for the full year of 2008, total revenue was RMB 1,741.1 ... the corresponding period in 2007. For the full year of 2008, operating income was RMB ... of 35.3% from RMB 263.9 million for the full year of 2007; -- Net income was RMB 51.7 ...3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
... to RMB154.6 million (US$22.7 million) for the full year 2008, as 3SBio further enhanced its ... of between US$43 million to US$45 million for the full year of 2009." Fourth Quarter and Fiscal ... and RMB162.1 million (US$23.8 million) in the full year of 2008. This was an increase of 44.3% and ...Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
... proprietary biomarkers. We expect to complete the full market launch of Clarient Insight(TM) Dx Breast ... strong revenue growth in 2009. We reiterate our full year 2009 revenue guidance of between $93 million ... million in the same quarter of 2007. For the full year 2008, operating expenses totaled $42.3 ...... patients, today announced its fourth quarter and full year financial results for 2008 and will host a ... to be completed in the third quarter of 2009. The full Phase 2b study will include an additional 330 ... loss of $3.0 million, or $0.12 per share. For the full year, net operating loss was $13.1 million, or ....
... and 12% for all products, respectively, for the full year 2008 as compared to 2007. We observed ... same period in 2007, and approximately 6% for the full year 2008 as compared to 2007. FDA Approval ... for the year ended December 31, 2008 and 2007. full audited consolidated financial statements and ...
... financial results for the fourth quarter and full year ended December 31, 2008. "The last ... (DBM) revenue of $2.6 million. Revenue for the full year ended December 31, 2008 was $103.8 million compared with $104.3 million for the full year 2007. Revenue for ...
Mindray Announces 2008 Fourth Quarter and Full Year Results
... results for the fourth quarter and full year ended December 31, 2008. The financial ... 2008. Highlights for Fourth Quarter and full Year 2008 -- full year 2008 revenue generated in China and ...ERT Reports Fourth Quarter and Full Year 2008 Results
... the fourth quarter of 2007. Net revenues for the full year 2008 were a record $133.1 million, up 34.9% ... year's quarter and were $10.1 million for the full year 2008 compared to $1.5 million in the prior ... quarter. The gross margin percentage for the full year was 55.8%, up from 50.7% in 2007. ...CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
... financial results for the fourth quarter and full year ended December 31, 2008. For the year ... "With the company's solid cash position, the full promotional launch of the improved U.S. Ranexa ... in the same quarter in the prior year. For the full year ended December 31, 2008, the company ...... Highlights full Year 2008 (1) Q4 2008 (1) Product ... New product sales shown as a percentage of 2008 full year/Q4 total Product sales. (2) New ... CER growth is calculated after restating full year/Q4 2008 results ...
Progen Concedes Shareholder Requisitioned Meeting
... - will not allow shareholder vote on full share buyback; and - persists with ... to achieve two outcomes: A full share buyback accessible to all Progen ... to put forward the first resolution proposing the full share buyback. The shareholder meeting has now ...BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
... million. "We achieved our first profitable full year in 2008, with an increase of 144 percent in ... The above results for the fourth quarter and full year of 2007 and 2008 and financial guidance for ... earnings per share for the fourth quarter and full year 2008 includes 26.3 million shares related to ...... which corrects cataracts and gives patients a full range of vision by flexing like the eye's natural ... lens implants procedures to give patients a full range of options when it comes to selecting the ... 733-2020 or (303) SEE-2020 ### Read the full story at ...
Other ContentsautomaticautomaticautomaticautomaticautomaticautomaticautomaticspellsspellsspellsholdingholdingholdingholdingholdingholdingholdingholdingbreathbreathbreathbreathbreathbreathbreathcriteriacriteriacriteriacriteriacriteriacriteriacriteriabeersshapingshapingshapingshapingOther Tags
(Date:11/5/2009)...rsity have developed synthetic molecules capable o...HIV-infected cells, as well as to prostate cancer ...urnal of the American Chemical Society , could lea...es. , The molecules called "antibody-recruitin...cruiting molecule targeting prostate cancer" (ARM-...
(Date:11/4/2009)...Long Beach and Riverside are responsible for a sig...a, and the true impact of air pollution and ship e...ated, according to researchers at the University o... appears in an online edition of the American Jou...t of all childhood asthma cases in Long Beach and ...
(Date:11/4/2009)...received more than $10 million in research grants ...stimulus program, bringing thetotal amount of stim...lion. Thirty-three projects achieved stimulus fun...er. , "The university has thoughtfully undertake...rly excellence to federal agency priorities. Thro...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2USC study finds big air pollution impacts on local communities 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 1Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 2Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 3Abbotts TRILIPIX 28R 29 28Fenofibric Acid 29 in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet 48164 4Cadient Group Brings Home the Gold and Two Bronze Aster Awards 12521 1Cadient Group Brings Home the Gold and Two Bronze Aster Awards 12521 2RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 1RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 2RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 3RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 4RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 5RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card 48161 6(Date:11/9/2009)...tCall/ - Hard To Treat Diseases (HTDS.PK) www.htd...$41 billion international healthcare company, is a...r, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.,...begin a five-year, $1 billion China initiative wit... its investment in its China R&D facility, and...
(Date:11/9/2009)...late when it comes to preventing or improving a di...ke Off Pounds Sensibly), the nonprofit weight-loss...(Vocus) November 9, 2009 -- Tomorrow may be too la...etes condition, according to TOPS Club, Inc. (Take...upport organization., , ,Diabetes is a disease in ...
(Date:11/9/2009)... positive influence of sports participation on bon...Vocus) November 9, 2009 -- As people age fractures...ch has highlighted the importance of exercise and ...However, a new study published in the November/Dec... Approach reveals that there may be significant g...
(Date:11/9/2009).../ -- Actress Mariska Hargitay and the Joyful Hea...to raise awareness about the need for domestic vio...ilding healing and wellness kits for women in cris... to each of the estimated 600 women currently bein...iolence shelters. ,, "Our goal is to shine a li...
(Date:11/9/2009)...assador ,, WHITE PLAINS, N.Y., Nov. 9 /PRNews..., was born so early and with so many underdevelope...ld survive -- or if he would ever walk, talk, see ...Dimes 2010 National Ambassador. ,, Joshua,s mo...motherhood and I was completely devastated. My hus...
Breaking Medicine News(10 mins):Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3[0] Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million[0] Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says[0] High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes [0] Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County[0] Six-Year-Old Survivor Fights for Preemies Like Himself
UnderwoodGatifloxacinExtraditionNinthSentinelWhitesBisphosphonatePuppetDesertificationLindsaysPapworthPrideChileanRheumatologists
Other Tagselusive 2residual 2pure 2pure 3business 2business 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |